Cephalosporin Drugs Market by Generation, Type, Route of Drug Administration and Application- Global Industry Analysis and Forecast to 2023

2018-05-30 / 3800.00 / Pharma & Healthcare / 110 Pages

Description

Industry Outlook and Trend Analysis

The global Cephalosporin Drugs Market has observed considerable growth in the recent years and is foreseen to encounter significant growth in the upcoming years. Cephalosporin is a bactericidal β-lactam anti-microbial, which is used to regard bacterial diseases, for example, skin infections, staph infections, pneumonia, bronchitis, gonorrhoea, tonsillitis, otitis media, and strep throat. Increment in rate of populace experiencing bronchitis, pneumonia, gonorrhoea, and tonsillitis boosts the market development. Also, increment in R&D exercises to grow profoundly proficient and safe medications and upsurge being used of mix treatments help the development of the market. Nonetheless, side effects related with cephalosporin and improvement of medication safe bacterial strains block the market development.

Drivers and Restraints

Rising number of individuals experiencing chronic diseases worldwide is the central point that boosts the market development. As per the 2016 appraisals of WHO, about one million sexually transmitted diseases (STIs) are reported each day all through the globe, representing more than 340 million new instances of sexually transmitted bacterial and protozoal contaminations in a year. Additionally, a 2016 research article expressed that urinary tract infections (UTI) are a very common bacterial diseases, which influence about 150 million individuals for each year all inclusive. Subsequently, ascend in predominance of different bacterial sicknesses build the consumer base for cephalosporin, which thus is foreseen to supplement the development of the cephalosporin drugs market.

Market Segmentation

The cephalosporin drugs market is segmented by generation, type, route of drug administration and application. Based on generation, the market is segmented into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. On the basis of type, it is sectioned into generics and branded. Based on route of drug administration, it is segmented into oral and injection. The applications include skin infection, respiratory tract infection, urinary tract infection, ear infection, sexually transmitted infection, and others.

Regional Outlook and Trend Analysis

Asia-Pacific is a lucrative market for cephalosporin drugs because of high populace base, existence of neglected therapeutic needs, and increment in discretionary income of individuals. Asia-Pacific is thickly populated, with India and China being the most populated nations.

Competitive Insights

The leading players in the market are Eli Lilly and Company, Lupin Limited, Sanofi, Allergan, GlaxoSmithKline, Merck & Co, Pfizer, Teva Pharmaceutical Industries, Roche Holding AG and Bristol-Myers Squibb. The market is extensively competitive with leading players investing in R&D activities, mergers and acquisitions.

The Cephalosporin Drugs Market is segmented as follows-

By Generation:


First-generation Cephalosporin
Second-generation Cephalosporin
Third-generation Cephalosporin
Fourth-generation Cephalosporin
Fifth-generation Cephalosporin


By Type:


Generics
Branded


By Route of Drug Administration:


Injection
Oral


By Application:


Ear Infection
Urinary Tract Infection
Respiratory Tract Infection
Skin Infection
Sexually Transmitted Infection
Others


By Region


North America



U.S
Canada
Mexico



Europe



Germany
France
UK
Italy
Spain
Rest of Europe



Asia-Pacific



Japan
China
Australia
India
South Korea
Rest of Asia Pacific



Rest of the World



Brazil
South Africa
Saudi Arabia
United Arab Emirates
Others


Some of the key questions answered by the report are:


What was the market size in 2014 and forecast from 2015 to 2023`
What will be the industry market growth from 2015 to 2023`
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast`
What are the major segments leading the market growth and why`
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition`

Table of Content

Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Rising prevalence of chronic diseases
3.2.2. Restraints
3.2.2.1. Side effects related with the medicines
3.2.3. Opportunities
3.2.3.1. Emerging Countries to Offer Lucrative Growth Opportunities
4. Cephalosporin Drugs Market , By Generation
4.1. Introduction
4.2. Global Cephalosporin Drugs Sales, Revenue and Market Share By Generation (2014-2017)
4.2.1. Global Cephalosporin Drugs Sales and Sales Share By Generation (2014-2017)
4.2.2. Global Cephalosporin Drugs Revenue and Revenue Share By Generation (2014-2017)
4.3. Cephalosporin Drugs Market Assessment and Forecast, By Generation, 2014-2023
4.4. First-generation Cephalosporin
4.4.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
4.5. Second-generation Cephalosporin
4.5.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
4.6. Third-generation Cephalosporin
4.6.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
4.7. Fourth-generation Cephalosporin
4.7.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
4.8. Fifth-generation Cephalosporin
4.8.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
5. Cephalosporin Drugs Market , By Type
5.1. Introduction
5.2. Global Cephalosporin Drugs Sales, Revenue and Market Share By Type (2014-2017)
5.2.1. Global Cephalosporin Drugs Sales and Sales Share By Type (2014-2017)
5.2.2. Global Cephalosporin Drugs Revenue and Revenue Share By Type (2014-2017)
5.3. Cephalosporin Drugs Market Assessment and Forecast, By Type 2014-2023
5.4. Generics
5.4.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
5.5. Branded
5.5.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
6. Cephalosporin Drugs Market , By Route of Drug Administration
6.1. Introduction
6.2. Global Cephalosporin Drugs Sales, Revenue and Market Share By Route of Drug Administration (2014-2017)
6.2.1. Global Cephalosporin Drugs Sales and Sales Share By Route of Drug Administration (2014-2017)
6.2.2. Global Cephalosporin Drugs Revenue and Revenue Share By Route of Drug Administration (2014-2017)
6.3. Cephalosporin Drugs Market Assessment and Forecast, By Route of Drug Administration 2014-2023 ($Million)
6.4. Injection
6.4.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
6.5. Oral
6.5.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
7. Cephalosporin Drugs Market , By Application
7.1. Introduction
7.2. Global Cephalosporin Drugs Sales, Revenue and Market Share By Application (2014-2017)
7.2.1. Global Cephalosporin Drugs Sales and Sales Share By Application (2014-2017)
7.2.2. Global Cephalosporin Drugs Revenue and Revenue Share By Application (2014-2017)
7.3. Cephalosporin Drugs Market Assessment and Forecast, By Application, 2014-2023 ($Million)
7.4. Ear Infection
7.4.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
7.5. Urinary Tract Infection
7.5.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
7.6. Respiratory Tract Infection
7.6.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
7.7. Skin Infection
7.7.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
7.8. Sexually Transmitted Infection
7.8.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
7.9. Others
7.9.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)
8. Cephalosporin Drugs Market , By Region
8.1. Introduction
8.2. Cephalosporin Drugs Market Assessment and Forecast, By Region, 2014-2023 ($Million)
8.3. Global Cephalosporin Drugs Sales, Revenue and Market Share by Regions
8.3.1. Global Cephalosporin Drugs Sales by Regions (2014-2017)
8.3.2. Global Cephalosporin Drugs Revenue by Regions (2014-2017)
8.4. North America
8.4.1. North America Cephalosporin Drugs Sales and Growth Rate (2014-2017)
8.4.2. Market Assessment and Forecast, By Country, 2014-2023 ($Million)
8.4.3. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.4.4. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.4.5. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.4.6. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.4.7. U.S.
8.4.7.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.4.7.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.4.7.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.4.7.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.4.8. Canada
8.4.8.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.4.8.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.4.8.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.4.8.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.4.9. Mexico
8.4.9.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.4.9.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.4.9.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.4.9.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.5. Europe
8.5.1. Europe Cephalosporin Drugs Sales and Growth Rate (2014-2017)
8.5.2. Market Assessment and Forecast, By Country, 2014-2023 ($Million)
8.5.3. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.5.4. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.5.5. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.5.6. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.5.7. Germany
8.5.7.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.5.7.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.5.7.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.5.7.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.5.8. France
8.5.8.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.5.8.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.5.8.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.5.8.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.5.9. UK
8.5.9.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.5.9.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.5.9.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.5.9.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.5.10. Italy
8.5.10.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.5.10.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.5.10.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.5.10.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.5.11. Spain
8.5.11.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.5.11.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.5.11.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.5.11.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.5.12. Rest of Europe
8.5.12.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.5.12.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.5.12.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.5.12.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.6. Asia-Pacific
8.6.1. Asia-Pacific Cephalosporin Drugs Sales and Growth Rate (2014-2017)
8.6.2. Market Assessment and Forecast, By Country, 2014-2023 ($Million)
8.6.3. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.6.4. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.6.5. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.6.6. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.6.7. Japan
8.6.7.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.6.7.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.6.7.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.6.7.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.6.8. China
8.6.8.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.6.8.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.6.8.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.6.8.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.7. Australia
8.7.1.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.7.1.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.7.1.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.7.1.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.7.2. India
8.7.2.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.7.2.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.7.2.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.7.2.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.7.3. South Korea
8.7.3.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.7.3.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.7.3.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.7.3.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.7.4. Rest of Asia-Pacific
8.7.4.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.7.4.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.7.4.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.7.4.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.8. Rest of the World
8.8.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)
8.8.2. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.8.3. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.8.4. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.8.5. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.8.6. Brazil
8.8.6.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.8.6.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.8.6.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.8.6.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.8.7. Turkey
8.8.7.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.8.7.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.8.7.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.8.7.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.8.8. Saudi Arabia
8.8.8.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.8.8.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.8.8.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.8.8.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.8.9. South Africa
8.8.9.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.8.9.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.8.9.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.8.9.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.8.10. United Arab Emirates
8.8.10.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.8.10.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.8.10.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.8.10.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
8.8.11. Others
8.8.11.1. Market Assessment and Forecast, By Generation, 2014-2023 ($Million)
8.8.11.2. Market Assessment and Forecast, By Type, 2014-2023 ($Million)
8.8.11.3. Market Assessment and Forecast, By Route of Drug Administration, 2014-2023 ($Million)
8.8.11.4. Market Assessment and Forecast, By Application, 2014-2023 ($Million)
9. Company Profiles
9.1. Eli Lilly and Company
9.1.1. Business Overview
9.1.2. Product Portfolio
9.1.3. Strategic Developments
9.1.4. Cephalosporin Drugs Sales, Revenue and Market Share
9.2. Lupin Limited
9.2.1. Business Overview
9.2.2. Product Portfolio
9.2.3. Strategic Developments
9.2.4. Cephalosporin Drugs Sales, Revenue and Market Share
9.3. Sanofi
9.3.1. Business Overview
9.3.2. Product Portfolio
9.3.3. Strategic Developments
9.3.4. Cephalosporin Drugs Sales, Revenue and Market Share
9.4. Allergan
9.4.1. Business Overview
9.4.2. Product Portfolio
9.4.3. Strategic Developments
9.4.4. Cephalosporin Drugs Sales, Revenue and Market Share
9.5. GlaxoSmithKline
9.5.1. Business Overview
9.5.2. Product Portfolio
9.5.3. Strategic Developments
9.5.4. Cephalosporin Drugs Sales, Revenue and Market Share
9.6. Merck & Co
9.6.1. Business Overview
9.6.2. Product Portfolio
9.6.3. Strategic Developments
9.6.4. Cephalosporin Drugs Sales, Revenue and Market Share
9.7. Pfizer
9.7.1. Business Overview
9.7.2. Product Portfolio
9.7.3. Strategic Developments
9.7.4. Cephalosporin Drugs Sales, Revenue and Market Share
9.8. Teva Pharmaceutical Industries
9.8.1. Business Overview
9.8.2. Product Portfolio
9.8.3. Strategic Developments
9.8.4. Cephalosporin Drugs Sales, Revenue and Market Share
9.9. Roche Holding AG
9.9.1. Business Overview
9.9.2. Product Portfolio
9.9.3. Strategic Developments
9.9.4. Cephalosporin Drugs Sales, Revenue and Market Share
9.10. Bristol-Myers Squibb
9.10.1. Business Overview
9.10.2. Product Portfolio
9.10.3. Strategic Developments
9.10.4. Cephalosporin Drugs Sales, Revenue and Market Share
10. Global Cephalosporin Drugs Market Competition, by Manufacturer
10.1. Global Cephalosporin Drugs Sales and Market Share by Manufacturer (2016-2017)
10.2. Global Cephalosporin Drugs Revenue and Market Share by Manufacturer (2016-2017)
10.3. Top 5 Cephalosporin Drugs Manufacturer Market Share
10.4. Market Competition Trend


Table of Figures

*You can glance through the list of Tables and Figures when you view the sample copy of Cephalosporin Drugs Market.

Request Sample

* mark fields are compulsory